<DOC>
	<DOCNO>NCT01734564</DOCNO>
	<brief_summary>In phase II study , patient solid tumor receive treatment hiltonol autologous dendritic cell .</brief_summary>
	<brief_title>Phase II Study With Hiltonol Dendritic Cells Solid Tumors</brief_title>
	<detailed_description>In phase II study , patient solid tumor receive treatment intratumoral hiltonol two cycle autologous dendritic cell load autologous tumor administer subcutaneously . A new cohort explore role radiation therapy , look abscopal effect .</detailed_description>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Confirmed diagnosis advance solid tumor Measurable disease Performance status 0 , 1 2 . Adequate renal , hepatic bone marrow function Availability tumor tissue , mature dendritic cell Clinically relevant disease infection . concurrent participation clinical trial administration antitumoral treatment Concurrent cancer , exception allow PI . Pregnant breast feeding woman immunosuppressant treatment know uncontrolled central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>